TBT - Cardiovascular Disease
Jul 19, 2024•24 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Welcome back Rounds Table Listeners!
In this throwback episode, Drs. Mike and John Fralick discuss the use of semaglutide in patients with obesity without diabetes and changes in renal function after starting dapagliflozin in patients with heart failure. Check it out below!
- Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (0:00 – 09:40).
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (09:40 – 19:24).
And for the Good Stuff:
- How Ozempic and Weight Loss Drugs Are Reshaping Denmark’s Economy (19:24 – 19:58).
- How a Canadian scientist and a venomous lizard helped pave the way for Ozempic (19:58 – 23:36).
Questions? Comments? Feedback? We’d love to hear from you! @roundstable
For the best experience, listen in Metacast app for iOS or Android